Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma

Bone Marrow Transplant. 2005 Aug;36(3):271-3. doi: 10.1038/sj.bmt.1705036.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • CD52 Antigen
  • Disease Progression
  • Glycoproteins / immunology
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Lymphoma, T-Cell / therapy*
  • Middle Aged
  • Prognosis
  • Recurrence
  • Remission Induction
  • Salvage Therapy
  • Stem Cell Transplantation
  • Time Factors
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab